MET alterations detected in blood-derived circulating tumor DNA correlate with bone metastases and poor prognosis
暂无分享,去创建一个
[1] S. Lippman,et al. Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary. , 2017, Cancer research.
[2] R. Kurzrock,et al. Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma , 2017, Clinical Cancer Research.
[3] Donavan T. Cheng,et al. Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.
[4] Dorota Kwapisz,et al. The first liquid biopsy test approved. Is it a new era of mutation testing for non-small cell lung cancer? , 2017, Annals of translational medicine.
[5] F. Saad,et al. Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] T. Powles,et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. , 2016, The Lancet. Oncology.
[7] Ash A. Alizadeh,et al. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients , 2016, Nature Communications.
[8] O. Harismendy,et al. Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients , 2016, Clinical Cancer Research.
[9] B. Kermani,et al. Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA , 2015, PloS one.
[10] F. Rojo,et al. Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer , 2015, Journal of Translational Medicine.
[11] Richard B. Schwab,et al. Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay , 2016, Oncotarget.
[12] Donavan T. Cheng,et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.
[13] K. Hess,et al. MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors. , 2015, Clinical genitourinary cancer.
[14] K. Hess,et al. Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit. , 2014, Clinical breast cancer.
[15] K. Hess,et al. Personalized Medicine and Imaging Analysis of 1 , 115 Patients Tested for MET Ampli fi cation and Therapy Response in the MD Anderson Phase I Clinic , 2014 .
[16] T. Kamoto,et al. Matriptase and MET are prominently expressed at the site of bone metastasis in renal cell carcinoma: immunohistochemical analysis , 2014, Human Cell.
[17] K. Nishio,et al. Targeting MET Amplification as a New Oncogenic Driver , 2014, Cancers.
[18] A. Iafrate,et al. Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC). , 2014 .
[19] Gary Box,et al. Preclinical evaluation of imaging biomarkers for prostate cancer bone metastasis and response to cabozantinib. , 2014, Journal of the National Cancer Institute.
[20] K. Hess,et al. MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit , 2014, Oncotarget.
[21] V. Servois,et al. Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma , 2014, International journal of cancer.
[22] T. Choueiri,et al. Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. , 2014, European urology.
[23] K. Hess,et al. MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors , 2013, Oncoscience.
[24] Michael Thomas,et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. , 2013, The New England journal of medicine.
[25] L. Mariani,et al. MET Gain in Diffuse Astrocytomas is Associated with Poorer Outcome , 2013, Brain pathology.
[26] M. Ratain,et al. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] W. Birchmeier,et al. Met, metastasis, motility and more , 2003, Nature Reviews Molecular Cell Biology.
[28] S. Scherer,et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas , 1997, Nature Genetics.
[29] N. Fausto. Hepatocyte growth factor receptor and the c-met oncogene Bottaro DP, Rubin JS, Faletto DL, Chan AM-L, Kmiecik TE, Vande Woude GF, Aaronson SA. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991;251:802?804 , 1991 .
[30] J. Rubin,et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. , 1991, Science.
[31] M. Braun,et al. Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[32] C. Cooper,et al. Molecular cloning of a new transforming gene from a chemically transformed human cell line , 1984, Nature.